The Next Generation Sequencing Services Market is expected to register a CAGR of 19.8% from 2024 to 2031 to reach $24.44 billion by 2031. The growth of this market is mainly driven by the declining costs of sequencing procedures, the development & approval of new targeted therapies, the rising prevalence of cancer, partnerships between NGS service providers & pharmaceutical companies, the high cost of implementing sequencing infrastructure, and technological advancements in NGS.